A Phase III Randomized, Multicenter, two arm, open label trial to evaluate the eddicacy of T-DM1 compared with treatment of physicians choice in patients with HER2-positive metastatic breast cancer who have
|Effective start/end date||7/20/11 → 6/30/16|
- Genentech Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.